Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Synovitis, Pigmented Villonodular 1Synovitis 1Solid Cancers 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Fallopian Tube Neoplasms 1Brenner Tumor 1Advanced Solid Tumors 1

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Immune Checkpoint Inhibitors 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Vitamin D 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1Grape Seed Extract 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Cancers × emactuzumab × Clear all
NCT02323191 2020-08-27

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
221 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡